tradingkey.logo

BRIEF-U.S. FDA Accepts Bristol Myers Squibb’S Supplemental BLA For Opdivo® Plus Yervoy®

ReutersFeb 24, 2025 1:26 PM

- Bristol-Myers Squibb Co BMY.N:

  • U.S. FOOD AND DRUG ADMINISTRATION ACCEPTS BRISTOL MYERS SQUIBB’S SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR OPDIVO® PLUS YERVOY® FOR PATIENTS WITH UNRESECTABLE OR METASTATIC MICROSATELLITE INSTABILITY-HIGH OR MISMATCH REPAIR DEFICIENT...

  • BRISTOL-MYERS SQUIBB CO - FDA ASSIGNS TARGET ACTION DATE OF JUNE 23, 2025

Source text: ID:nBw2tnHFDa

Further company coverage: BMY.N

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI